【序号】：1 【作者】：Grob JJ, Amonkar MM, Karaszewska B，et, al. 【题名】：Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial 【期刊】：Lancet Oncol. 【年、卷、期、起止页码】：2015 Oct;16(13):1389-98 【全文链接】：http://www.ncbi.nlm.nih.gov/pubmed/26433819 【序号】：2 【作者】：Latimer NR1, Amonkar MM, Stapelkamp C, Sun P 【题名】：Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma 【期刊】：Melanoma Res. 【年、卷、期、起止页码】：2015 Dec;25(6):528-36. 【全文链接】：http://www.ncbi.nlm.nih.gov/pubmed/26340744 【序号】：3 【作者】：Long GV1, Stroyakovskiy D2, Gogas H3, et,al. 【题名】：Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial 【期刊】：Lancet 【年、卷、期、起止页码】：2015 Aug 1;386(9992):444-51 【全文链接】：http://www.ncbi.nlm.nih.gov/pubmed/26037941
【序号】：4 【作者】：Schadendorf D1, Amonkar MM2, Stroyakovskiy D, et,al. 【题名】：Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. 【期刊】：Eur J Cancer 【年、卷、期、起止页码】：2015 May;51(7):833-40. 【全文链接】：http://www.ncbi.nlm.nih.gov/pubmed/25794603
【序号】：5 【作者】：Menzies AM1, Ashworth MT2, Swann S, et,al. 【题名】：Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial 【期刊】：Ann Oncol. 【年、卷、期、起止页码】：2015 Feb;26(2):415-21 【全文链接】：http://www.ncbi.nlm.nih.gov/pubmed/25411413
应助达人
迎国庆送壕礼！十月发帖抢大疆云台
【官方邀请】高效液相色谱使用情况有奖调研
喜迎国庆！第十七届原创大赛超级原创日参赛奖励翻倍
丹纳赫四十周年寄语征集领大礼包
